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ABSTRACT: Systemic corticosteroid therapy may affect diaphragm structure and
function. We postulated that functional, immunohistochemical and biochemical char-
acteristics of rat diaphragm were less affected by alternate-day methylprednisolone
(MP) administration, and more by repeated bursts of MP, in comparison to daily
s.c MP.
Sixty adult rats were randomized into four groups: saline s.c.; MP continuously
(MP-C), 1 mg·kg-1 daily, MP alternate-day therapy (MP-A), 2 mg·kg-1 every other
day; or MP in bursts (MP-B), MP 2 mg·kg-1 daily for 2 weeks, saline for 4 weeks,
MP 2 mg·kg-1 daily for 2 weeks. The total treatment period was 8 weeks. Contractile
properties of isolated diaphragm strips were measured. Antibodies reactive with
type I, IIa, IIx and IIb myosin heavy chains were used for immunohistochemical
analysis.  Biochemical evaluation included markers of fast energy supply, glycogeno-
lytic activity, β-oxidation capacity and oxidative capacity.
The force-frequency curve was depressed in all MP groups. Fibre type I, IIx and
IIb cross-sectional area (CSA) decreased in all MP groups.  Burst therapy decreased
the contribution of type IIb fibres to total diaphragm muscle area. MP-A affected
glycogenolytic activity less than MP-C. Burst MP therapy reduced creatine kinase
(CK) activity and β-oxidation capacity compared to MP-C. Oxidative capacity was
increased in all MP groups.
In conclusion, although the methylprednisolone treatment regimens affected
diaphragm muscle morphology and bioenergetic enzyme activities in different ways,
force generation decreased in all methylprednisolone treated groups to the same
extent.
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Recently, animal and clinical studies have shown evi-
dence of respiratory muscle dysfunction induced by treat-
ment with corticosteroids [1, 2]. Morphological changes,
such as selective type IIb fibre atrophy, were observed
in animal studies following administration of fluorina-
ted steroids [3, 4]. Nonfluorinated steroids, however, caused
loss of diaphragm function without muscle atrophy, sug-
gesting myopathy [4].
The mechanisms by which nonfluorinated steroids cause
myopathy are in part unknown. Changes in myosin heavy
chain composition in the muscle fibres may contribute,
since myosin heavy chain turnover rate in muscle cells
was decreased following dexamethasone therapy [5].
These myosin heavy chains determine myosin adenosine
triphosphatase (ATP-ase) activity and the speed of shorte-
ning in the muscle fibres and are, therefore, partly respon-
sible for contractile properties.  POLLA et al. [6] reported
a complete disappearance of rat diaphragm muscle fibres
containing IIb myosin heavy chains (MyHCs) following
cortisone acetate 100 mg·kg-1·day-1 for 11 days.  It is not
known whether similar changes occur after administra-
tion of lower, clinically more relevant dosages.
Changes in energy substrate and enzyme activities
may also contribute to the onset of steroid-induced myopa-
thy. A consistent observation is the increase in glycogen
content in the diaphragm [7, 8]. However, conflicting
effects on diaphragm mitochondrial function were found
following corticosteroid therapy [9, 10]. This may be
explained by the differences in the dosage, duration, and
types of steroids studied.
In addition, the severity of structural and biochemical
changes in the respiratory muscles may depend on the
treatment regimens applied. Alternate-day glucocorticoid
therapy may reduce side-effects, since anti-inflamma-
tory potency appears to persist longer than the undesir-
able metabolic effects [11, 12]. The clinical efficacy of
alternate-day therapy was similar in patients with chronic
obstructive pulmonary disease (COPD) or stable asthma
compared to daily treatment [13, 14]. Another treatment
regimen, short-term high-dose steroid therapy is often
applied during exacerbations of COPD or asthma. Repea-
ted episodes of high-dose steroid administration, in this
study referred to as "bursts", may cause more severe side-
effects. This concept is supported by the observation that
recovery from acute steroid myopathy, caused by short-
time high-dose steroid administration, appears to take
several months [15]. Such a prolonged recovery period
was also shown in a recent animal study [16].
We postulate that the structure and function of the rat
diaphragm: 1) is less affected by alternate-day corticos-
teroid administration; and 2) is more affected by repea-
ted bursts, in comparison to daily administration.  In order
to test this hypothesis, we studied functional, immuno-
histochemical and biochemical changes in rat diaphragm
induced by continuous, alternate-day and burst admini-
stration of the nonfluorinated steroid, methylpredniso-
lone.
Methods
Study design, animals and treatment
Sixty adult male outbred Wistar rats, aged 18–20 weeks,
mean (±SD) weight 525±35 g, were randomized into four
groups: 
control (C), saline 0.2 mL·day-1 s.c.; 
methylprednisolone (MP) continuously (MP-C), MP 1
mg·kg-1·day-1 s.c.; 
MP alternate-day therapy (MP-A), MP 2 mg·kg-1 s.c.
every other day alternating with saline 0.2 mL s.c.; MP
in bursts (MP-B), MP 2 mg·kg-1·day-1 s.c. for 2 weeks
followed by saline 0.2 mL s.c. for 4 weeks and by MP
2 mg·kg-1·day-1 s.c. for 2 weeks.
Each injection was of similar volume (~0.2 mL). Over
8 weeks, the animals were injected s.c. daily between
8.30 h and 1000 h in the neck. The total dose of steroids
administered was equal in all treatment groups. The rats
were fed ad libitum, maintained on a 12/12 h light-dark
regimen, and weighed twice weekly. At the end of the
treatment period, contractile properties, immunohisto-
chemical and biochemical characteristics of the diaphragm
were examined. All animals were investigated between
23 and 30 h after the last injection. Adrenal and diaphragm
weights were measured immediately following dissec-
tion. The study was approved by the local Animal Experi-
ments Committee of the University of Nijmegen.
Contractile properties
The rats were anaesthetized with sodium pentobarbital
(70 mg·kg-1 i.p.) and a polyethylene cannula was inser-
ted through a tracheotomy. The animals were mechani-
cally-ventilated with an oxygen-enriched gas mixture
(airflow 0.5 mL·g-1 body weight·min-1, respiratory freque-
ncy 70 breaths·min-1, and a duty cycle 50%). The diaph-
ragm was quickly removed through a combined laparotomy
and thoracotomy and was immediately immersed in a
cooled, oxygenated Krebs solution at a pH of 7.4. This
solution consisted of (mmol·L-1): 137 NaCl, 4 KCl, 2
MgCl2, 1 KH2PO4, 24 NaHCO3, 2.7 CaCl2, and 7 glu-
cose. D-tubocurarine chloride 25 µM (Sigma Chemicals,
The Netherlands) was added to prevent spontaneous neuro-
muscular activity. 
Two small rectangular bundles, parallel to the long
axis of the muscle fibres, were dissected from the middle
part of the lateral costal region of each hemidiaphragm.
Silk sutures were firmly tied to both ends of the bundle
to serve as anchoring points. Each bundle was placed in
a tissue bath between two large platinum stimulating
electrodes. The tissue baths were filled with Krebs solu-
tion at 37°C and were oxygenated with 95% O2 and 5%
CO2. The central tendon insertion of the bundles was
tied to a fixed point and the costal margin origin to an
isometric force transducer (Sensotec, model 31/1437;
Columbus, OH, USA). Data acquisition and storage were
performed using a Dash-16 interface and Twist-Trigger
software (I.D.-electronics, University of Nijmegen, The
Netherlands).  Stimulations were applied with a Grass S
48 stimulator (Quincy, MA, USA). Maximal twitch force
was reached at 34 V. To ensure supramaximal stimula-
tion, subsequent stimulations were performed with a 20%
higher voltage (40 V). The pulse duration was set on 0.2
ms. Twitch stimuli were used to determine the optimal
length (Lo), followed by a 15 min thermoequilibration per-
iod [17]. The following measurements were made.
Twitch characteristics.  Two twitches were recorded at Lo
to obtain maximal twitch tension (Pt), contraction time
(CT), and half relaxation time (1/2RT). The averages were
used for further analysis.
Maximal tetanic contraction.  Two maximal tetanic stim-
uli (with a frequency of 160 Hz and a train duration of
250 ms) were generated to obtain maximal tetanic ten-
sion (Po).
Force-frequency (FF) protocol.  Muscle bundles were
stimulated every 2 min with the following order of fre-
quencies: 25, 160, 50, 160, 80, 160, 120 and 160 Hz
(train duration 250 ms). Forces were also expressed as
percentage of the average force at 160 Hz before and
after each stimulus [4, 18].
The generated force was expressed per cross-sectional
area (kg·cm-2). Cross-sectional area (CSA) was measured
by dividing diaphragm bundle weight by muscle den-
sity (1.056 mg·mm-3) and bundle length.
Immunohistochemical procedures
Muscle strips obtained from the costal part of the right
hemidiaphragm were embedded in Tissue-Tek® in a plas-
tic holder. The muscle fibres were oriented parallel to
the long side of the holder. Subsequently, these speci-
mens were quickly frozen in isopentane cooled in liquid
N2, followed by further freezing in liquid N2. Serial cross-
sections were cut at 7 µm with a cryostat kept at -30°C.
Antimyosin heavy chain antibodies (Regeneron Pharma-
ceuticals, New York, USA) were used for morphometric
examination. The following antibodies were used: BA-
D5 reactive with type I MyHCs; SC-71 reactive with
type IIa MyHCs; BF-35 reactive with type I, IIa and IIb
but not with type IIx MyHCs; and BF-F3 reactive with
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type IIb MyHCs [19]. Incubation with antimyosin heavy
chain antibodies was performed at room temperature for
1 h. Antibodies were subsequently labelled with ultra
small immunogold reagent followed by silver enhance-
ment (Aurion, Wageningen, The Netherlands). A mini-
mum of 300 fibres was analysed from each diaphragm
using a Sprynt-based, PC-Image digital analysis system
(Bos B.V., Waddinxveen, The Netherlands).
Biochemistry
Parameters of the bioenergetic capacity of the diaphragm
included the activities of creatine kinase (CK), respon-
sible for the fast energy supply, the glycogenolytic
enzyme phosphorylase, and the mitochondrial enzymes
3-hydroxyacyl-CoA dehydrogenase (HADH), a marker
for the β-oxidation capacity, and citrate synthase (CS),
an index of citric acid cycle activity.
Fat and tendon were quickly removed from remains
of the left and right hemidiaphragm. Subsequently, these
diaphragm parts were frozen in liquid N2 and stored at
-80°C.  Segments of freshly frozen diaphragm were
thawed in ice-cooled buffer containing 250 mM sucrose,
2 mM ethylenediamine tetra-acetic acid (EDTA) and 10
mM Tris-HCl (pH 7.4). In this buffer, muscle homogen-
ates (5% wt·vol-1) were prepared by hand homogeniza-
tion, using a Potter-Elvehjem glass-teflon homogenizer.
CK activity was determined with the Boehringer CK-
NAC activated kit [20], and expressed in mmol reduced
nicotinamide adenine dinucleotide phosphate (NADPH)
formed·min-1·g tissue. Total phosphorylase (a+b) acti-
vity was assayed according to the method described by
JACOBS and co-workers [20]. Phosphorylase activity
was expressed as µmol NADPH formed·min-1·g tissue.
HADH activity was assessed at 50 µM acetoacyl-CoA
[22] and expressed in nmol HADH oxidized·min-1·g tis-
sue. CS activity was determined at 25°C [23], and was
expressed as µmol coenzyme A (CoA) formed·min-1·g
tissue. All other above-mentioned measurements were
performed at 37°C. The assays for metabolic enzymes
were performed spectrophotometrically in duplicate. The
coefficient of variation for the assays applied was ~5%.
Data analysis
Data of contractile properties of the two bundles obtained
from one rat were averaged.  The Statistical Package for
the Social Sciences (SPSS)/PC+ package V5.0.1 (Chicago,
Ill, USA) was used for statistical analysis. Data were
compared using one-way analysis of variance (ANOVA)
followed by Duncan's multiple-range test. Repeated mea-
sures ANOVA was used for growth curve analysis, and
a two-way ANOVA was used to detect treatment dif-
ferences in force generation during the FF protocol.
Results were considered significant at p-values less than
0.05. Data are expressed as mean±SD.
Results
Body, muscle and adrenal weight
Figure 1 shows the body weight curve during the 8
week treatment period. A significant effect of steroid
treatment on growth curve was noted throughout this per-
iod (p=0.039). Continuous MP administration affected
body growth most. Body weights of the MP-A animals
closely tracked those of the control group. Administra-
tion in bursts temporarily inhibited growth.
No differences in absolute diaphragm weights were ob-
served. Diaphragm weight, normalized for body weight,
was also similar in all groups (Control 0.0132±0.001%;
MP-C 0.0143±0.001%; MP-A 0.0136±0.001%; MP-B
0.0141±0.002%). Absolute adrenal weight was reduced
in all MP treatment groups. Adrenal weights in the treat-
ment groups were reduced in proportion to body weight
(Control 0.0082±0.0014%; MP-C 0.0077±0.0008%; MP-
A 0.0074±0.0007%; MP-B 0.0079±0.001%).
Contractile properties
Diaphragm bundle dimensions did not differ between
the four groups (average length ~16.5 mm, thickness ~0.67
mm, width ~1.8 mm, and weight ~26 mg). Pt and Po,
normalized for CSA, decreased by 7.0–9.5% in all MP
groups (p=0.07). Twitch characteristics did not differ
between the groups (table 1).
The FF curves, expressed as absolute values, showed
significant differences in force generation (p=0.026) in
all groups treated with MP. Force generation was equ-
ally reduced in all MP groups (fig. 2). MP treatment affec-
ted force generation at all stimulation frequencies in a
similar way. The percentage decrease in force production
of the final 160 Hz stimulation during the FF protocol
was similar in the three MP groups, and did not differ
from control (MP-C 11.4±10.0%; MP-A 11.7±7.5%; MP-
B 12.5±11.0%; Control 9.0±7.7%).
Immunohistochemistry
Methylprednisolone administrated in bursts (MP-B)
caused a shift in fibre distribution from type IIb to type
IIx in comparison to control (p<0.05) (table 2).
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Fig. 1.  –  Mean growth curve for the four groups.    ❍ : control;  
■ : MP-C;    ❏ : MP-A;    ▲ : MP-B; -------: pooled stan-
dard deviation (p=0.039). MP: methylprednisolone; MP-C: MP con-
tinuously, 1 mg·kg-1 daily; MP-A: MP alternate day therapy, 2 mg·kg-1
every other day; MP-B: MP in bursts, 2 mg·kg-1 daily for 2 weeks,
saline for 4 weeks, MP 2 mg·kg-1 for 2 weeks.
Significant atrophy of type I, IIx and IIb fibres was
observed in all MP groups (fig. 3). The differences in
type IIa fibre CSA, as shown in figure 3, were signifi-
cant but very small. The degree of type IIx atrophy was
less following alternate-day in comparison to continuous
MP therapy. In addition, type IIx CSA decreased in the
MP-B group compared to MP-C. Thus, type IIx fibre
atrophy was most pronounced following bursts and least
affected by alternate-day steroid therapy compared to
daily treatment (fig. 3). In contrast, the degree of type
IIb fibre atrophy was greater in the MPA animals com-
pared to MP-C.
As a result of the decrease in number of type IIb fibres
in the MP-B group, the relative contribution of type IIb
fibres to the total muscle area of the diaphragm was
decreased compared to control (fig. 4).
Biochemistry
The data on bioenergetic enzyme activities are shown
in table 3. An approximately 30% increase in CS acti-
vity was found in all MP treatment groups, indicating an
increased oxidative capacity (p<0.01).
Treatment with the three MP regimens affected energy
supply by different mechanisms. Firstly, continuous steroid
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Table 1.  –  Diaphragm contractile properties
Treatment               Pt CT                1/2RT                    Po Pt/Po
kg·cm-2 ms                    ms                   kg·cm-2
Control 0.64 (0.18) 29.3 (1.8) 17.7 (1.3) 2.23 (0.51) 0.29 (0.03)
MP-C 0.58 (0.20) 28.8 (2.1) 17.9 (1) 2.02 (0.65) 0.29 (0.02)
MP-A 0.60 (0.15) 29.2 (2.3) 18.1 (1.1) 2.07 (0.42) 0.29 (0.03)
MP-B 0.59 (0.23) 29.2 (2.6) 18.1 (1.6) 2.02 (0.74) 0.29 (0.04)
Pt: twitch tension; CT: contraction time; 1/2RT: half relaxation time; Po: maximal tetanic tension; MP: methyl-
prednisolone; MP-C: MP continuously, 1 mg·kg-1 daily; MP-A: MP alternate-day therapy, 2 mg·kg-1 every
other day; MP-B: MP in bursts, 2 mg·kg-1 daily for 2 weeks, saline for 4 weeks, MP 2 mg·kg-1 for 2 weeks.
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Fig. 2.  –  Force-frequency curve.    ❍ : control;    ■ : MP-C;  
❏ : MP-A;    ▲ : MP-B; ------- : pooled standard deviation.
For abbreviations see legend to figure 1.
Table 2.  –  Fibre type distribution
Type I     Type IIa      Type IIx     Type IIb
Treatment        %            %             %             %
Control 32.7 (4.1) 33.5 (4.2) 28.3 (4.1) 5.5 (4.3)
MP-C 33.4 (3.6) 31.6 (6.1) 31.4 (4.2) 3.7 (3.7)
MP-A 34.6 (3.5) 33.4 (3.9) 28.7 (3.5) 3.3 (3.6)
MP-B 33.6 (3.1) 31.5 (3.5) 33.2 (4.9)# 1.8 (2.0)*
*: p<0.05, compared to control; #: p<0.05, compared to control
and the MP-A group.  For abbreviations see legend to table 1.
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Fig. 3.  –  Fibre type cross-sectional area (CSA).     : control;     :
MP-C;      : MP-A;      : MP-B.  *: p<0.05, compared to control; #:
p<0.05, compared to MP-C.  For abbreviations see legend to figure 1.
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Fig. 4.  –  Relative fibre type contribution to the total muscle area of
the diaphragm.     : control;     : MP-C;     : MP-A;     : MP-B. *:
p<0.05, compared to control. For abbreviations see legend to figure 1.
administration decreased glycogenolytic activity, indi-
cated by a decrease in phosphorylase activity. Secondly,
glycogenolytic activity was less affected following alter-
nate-day steroid administration in comparison to daily
treatment. Finally, burst MP administration affected CK
activity and β-oxidation capacity, as indicated by HADH,
more in comparison to MP-C. Total phosphorylase acti-
vity, however, was higher in the MP-B group than in the
MP-C group.
Discussion
The question in the present study was whether there
were differences in changes in rat diaphragm following
different corticosteroid treatment regimens. The data
showed that the MP treatment regimens affected body
weight, diaphragm morphology and bioenergetic capa-
city in a different way. Force generation, however, decrea-
sed to a similar extent in all MP treatment regimens. This
apparent discrepancy can be explained by the fact that
the net result of these combined morphometric and bio-
chemical changes was an equal reduction in force gen-
eration.
Rationale of methylprednisolone dosage
The rationale for the dose of MP used in the present
study was based on an absorption of 60% after i.m. injec-
tion [18], and the finding that the s.c. route may require
higher doses to produce effects similar to i.m. adminis-
tration [24]. Similar anti-inflammatory potency and meta-
bolism of methylprednisolone have been described in rats
and humans [25, 26]. Therefore, 1 mg·kg-1 of MP, as
administrated in the MP-C group, may be equivalent to
a dose of 35 mg·day-1 in a 60 kg human. A daily dose
of 35 mg methylprednisolone is not uncommon in the
treatment of patients with COPD during an exacerbation
[27].
The duration of biological effects of methylpredniso-
lone in rat is difficult to analyse because of the nonlin-
ear clearance [28]. In addition, no close correlation was
found between the circulating half-life of a glucocorti-
coid and its duration of action [12]. However, the dif-
ferences in growth curves observed in the present study
indicate that there are differences in biological effects
between continuous and alternate-day therapy.
Contractile properties
The reduction in diaphragm force generation follow-
ing MP therapy, observed in this study during the FF
protocol, cannot be explained by differences in oxy-
genation of the bundles, since their measures were simi-
lar in all groups.  Since MP has little or no mineralocorticoid
activity, an overestimation of the CSA due to an increase
in extracellular fluid is unlikely. Glucocorticoids are known
to cause protein wasting [29]. A reduction in myofibril-
lar protein density would result in a reduction in the num-
ber of cross-bridges available for interaction with actin.
This can lead to a reduction in force generation. Other
plausible causes for the impairment in diaphragm force
are the morphological and biochemical changes.
In previous studies, no changes in twitch and maxi-
mal tetanic tension were found following 0.5 mg·kg-1
daily MP for 6 weeks [17], or following 5 mg·kg-1 daily
prednisolone for 4 weeks [4].  In addition, cortisone ace-
tate, 100 mg·kg-1·day-1 for 10 days, did not lead to func-
tional changes in the diaphragm [18]. The downward
shift of the FF curve in the present study may be explained
by differences in effects of dosage and duration of the
steroid therapy on morphological and biochemical char-
acteristics (see below).
Immunohistochemistry
Immunohistochemical differentiation between type IIx
and IIb fibres, as performed in this study, may be of
importance since type IIx and IIb MyHCs possess bio-
chemical and functional differences. Maximum velocity
of shortening [30] and resistance to fatigue [31] in type
IIx muscle fibres are intermediate between those of type
IIa and IIb fibres. Twitch and tetanic tension are higher
in IIb in comparison with IIa and IIx motor units [31].
Type IIx muscle fibres have a rich mitochondrial con-
tent, in contrast to type IIb fibres [19].
In support of our hypothesis, the degree of type IIx
atrophy was less following alternate-day MP adminis-
tration compared to continuous therapy. On the other
hand, type IIb fibre atrophy was more pronounced in the
alternate-day group. Cortisone acetate treatment in rab-
bits resulted in atrophy of all diaphragm fibre types [32],
whereas no changes in fibre CSA were found in rats fol-
lowing prednisolone treatment [4]. Muscle fibre atrophy
can be the result of steroid-induced protein wasting due
to a reduction in protein synthesis and an increase in
intracellular proteolysis [29]. However, muscle fibre atro-
phy may also occur as an attempt to increase oxygen
delivery by decreasing the cell diameter, in this way cre-
ating a smaller diffusion distance [33].
Burst therapy reduced the number of type IIb fibres
and decreased the contribution of type IIb fibres to total
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Table 3.  –  Biochemical analysis of the diaphragm
CK               Phosphorylase              HADH                   CS
Treatment             kU·g-1 U·g-1 U·g-1 U·g-1
Control 2.18 (0.54) 35.5 (3.3) 2.86 (0.44) 23.9 (2.3)
MP-C 1.82 (0.64) 32.6 (2.0)# 2.83 (0.66) 30.8 (6.5)*
MP-A 1.48 (0.32)* 38.0 (3.2) 2.84 (0.51) 31.2 (4.0)*
MP-B 1.39 (0.47)*‡ 37.2 (4.0) 2.24 (0.35)# 30.6 (4.8)*
CK: creatine kinase; HADH: 3-hydroxyacyl-CoA dehydrogenase; CS: citrate synthase.  For fur-
ther abbreviations see legend to table 1. *: p<0.01, compared to control;  ‡: p<0.05, compared
to MP-C; #: p<0.01, compared to all other groups.
diaphragm muscle area. Cortisone acetate administration
(100 mg·kg-1 daily for 11 days) actually resulted in a com-
plete disappearance of fibres containing IIb MyHCs, while
fibre type distribution was not described [6]. These
changes were not detected using ATP-ase staining [4, 32].
The cause of the shift from type IIb to type IIx fibres
following burst therapy is not entirely clear. This shift
may be caused by a disappearance of type IIb fibres com-
bined with an appearance of new type IIx fibres. The
following observations, however, support the occurrence
of a transformation from type IIb to IIx fibres. Corticoste-
roids decrease the rate of amino acid incorporation into
the MyHCs, resulting in a decreased turnover rate of the
MyHCs in the muscle cell. As this decrease in turnover
rate is most pronounced in the fast twitch muscle fibres
[5], type IIb fibres are likely to be affected most. This
may lead to a decrease in IIb MyHCs in type IIb fibres.
Since genes of IIx MyHCs are coexpressed in a number
of type IIb muscle fibres [34], an increase of IIx MyHCs
in type IIb muscle fibres may occur to compensate for
the decrease in type IIb MyHCs. To our knowledge, there
is no evidence that type IIb fibres disappear while new
type IIx fibres are generated. The shift from type IIb to
type IIx fibres following MP burst therapy is probably
too small to cause functional changes at different stimu-
lation frequencies.
Biochemistry
Treatment with MP resulted in a decrease in energy
supply, as indicated by a reduction in CK activity or in
glycogenolytic activity. This impairment in energy sup-
ply may have caused the increase in oxidative capacity
in all MP groups. To what extent these differences in
biochemistry were influenced by the fact that animals in
the MP-A and MP-B group received 2 mg·kg-1 MP 23
to 30 h before investigation, whereas, animals in the MP-
C group only received 1 mg·kg-1, is not clear.
Creatine kinase rapidly rephosphorylates adenosine
diphosphate (ADP) from phosphocreatine in order to keep
a constant adenosine triphosphate (ATP) level in the mus-
cle. A decrease in CK activity may, therefore, lead dir-
ectly to a reduction in fast energy supply. CK activity
decreased following steroid administration in bursts com-
pared to MP-C. In patients with bronchial asthma, CK
activity in the deltoid muscle decreased following pred-
nisone treatment (17 mg·day-1 for 15 yrs) [8].
The increase in glycogen storage in the diaphragm mus-
cle following steroid administration found by FERGUSON
et al. [35] may be the result of a decrease in glycogen
breakdown, or an increase in glycogen production [7],
or both [8]. Our data show that alternate-day and burst
therapy did not affect glycogenolytic capacity, measured
by phosphorylase activity, in contrast to continuous steroid
administration.
Since the diaphragm muscle possesses a high β-oxida-
tion capacity [36], it is unclear whether the 20% reduction
in HADH activity, observed following steroid adminis-
tration in bursts, has functional consequences. Short-term
(10 days) prednisolone treatment (5 mg·kg-1 daily s.c.)
did not change HADH activity in rat diaphragm [9].
However, a decrease in HADH activity in vastus later-
alis muscle of patients with rheumatoid arthritis occurred
with low doses of prednisolone [37].
In the present study, administration of methylpred-
nisolone resulted in an increase in oxidative capacity, as
indicated by the increased CS activity, independent of
the treatment regimen applied. This is in line with the in-
crease in oxidative staining reaction in skeletal muscle
reported by others [10]. Mitochondrial changes in rabbit
diaphragm, following glucocorticoid administration,
ranged from a numerical increase to the presence of
enlarged and degenerated mitochondria [38].  In contrast
to these observations, CS activity in rat diaphragm was
reduced following 5 mg·kg-1 prednisolone daily for 10
days. However, no changes in CS activity were repor-
ted following 0.5, 1 or 2 mg·kg-1 daily [9], suggesting
that enzyme activity was affected more using high dos-
ages of prednisolone in comparison to low dosages.
Reactions of metabolism to corticosteroids may also
depend on the fibre type composition of the muscle [9,
35], because the resistance of different fibre types is
believed to depend on their ability to compensate the
steroid-induced deficiency of the glycogenolytic route by
converting to oxidative metabolism [10].
In conclusion, force generation decreased in all methyl-
prednisolone treated groups to an equal extent, although
the methylprednisolone treatment regimens affected dia-
phragm muscle morphology and bioenergetic enzyme
activities in a different way.
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